Skip to content
Narrow screen resolution Wide screen resolution Increase font size Decrease font size Default font size
Home Page arrow Divisions arrow Biodiagnostic Sciences and Technologies
Biodiagnostic Sciences and Technologies PDF Print E-mail
Article Index
Biodiagnostic Sciences and Technologies
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7


Resources – Critical mass assembly

Significant assets and strengths of the group are:
  • Over 25 years experience of the staff in the development and production of in vitro diagnostics,
  • Comprehensive and highly integrated platform for gene- to-protein biomarker discovery, target validation (disease models) and diagnostics (biosensing devices),
  • Exemplary multidisciplinary profile of the team that is unique to the region and has fostered multiple synergies and cross-thematic collaborations with other Institutes and academic partners both in Greece, and abroad, and
  • Significant research dissemination and outreach record of highly specialized scientific services directed to the public at large.
More specifically:
  • Over 25 years experience in development of immunoreagents, materials, immunoassays and immunosensors for biodiagnostic applications, in cytogenetics as well as in molecular diagnostics gained through coordination/participation in multiple European, National and International projects and networks.
  • Appropriate advanced infrastructure complemented by infrastructure available at other institutes of NCSR Demokritos.
  • Already approved research funding gained through 5 EU and 8 GRST research projects, which started in 2013 (or late 2012), with a budget for the Biodiagnostics Sciences and Technology Division exceeding 3000 k€.
  • Funding through provision of specialized scientific services on Cytogenetics, Molecular Diagnostics and external Quality Control of Radioimmunoassays with a revenue of approximately 200 k€ per year.